Hydrocortisone in Hormone Replacement Therapy for Large Pituitary Neuroendocrine Tumors

Study Purpose

The goal of this clinical trial is to assess the need for hydrocortisone replacement therapy during the perioperative period for large pituitary neuroendocrine tumors. The main questions it aims to answer are: • Does hydrocortisone replacement therapy reduce the incidence of adrenal insufficiency in participants? Researchers will compare hydrocortisone to a placebo (a look-alike substance that contains no drug) to see if hydrocortisone works to reduce the incidence of adrenal insufficiency. Participants will:

  • - Take or intravenous infusion drug hydrocortisone or a placebo every day for 2 weeks.
  • - Visit the clinic three months after surgery for checkups and tests.
- Keep a diary of their symptoms

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

No
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

Interventional
Eligible Ages 18 Years - 70 Years
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria:

  • - (1) Age range: 18-70 years old; - (2) Accept PitNETs patients who can be treated with endoscopic transsphenoidal surgery; - (3) The maximum diameter of the tumor is ≥ 2 centimeters; - (4) Preoperative hypothalamic pituitary adrenal axis integrity; - (5) The subject or their legal representative signs the informed consent form.

Exclusion Criteria:

- (1) Patients with a history of Cushing's disease or adrenal insufficiency; - (2) Emergency and combined hormone therapy patients; - (3) Pituitary stroke patients; - (4) Patients lacking head magnetic resonance imaging;

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

NCT06679816
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

Phase 4
Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

Beijing Tiantan Hospital
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

N/A
Principal Investigator Affiliation N/A
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Other
Overall Status Recruiting
Countries China
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

Pituitary Adenoma, Pituitary Neuroendocrine Tumor
Arms & Interventions

Arms

Experimental: Hormone supplementation therapy group

Placebo Comparator: Placebo therapy group

Interventions

Drug: - Hormone replacement therapy

Perioperative Hydrocortisone Reduction Therapy

Drug: - Placebo

Perioperative placebo Reduction Therapy

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

International Sites

Beijing, Beijing, China

Status

Recruiting

Address

Beijing, Beijing Tiantan Hospital,Capital Medical University

Beijing, Beijing, 100070

Site Contact

xingchao wang, Dr

[email protected]

15101053127

Stay Informed & Connected